📰 Toby Maher News
Page 4 - Toby Maher News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Toby Maher. Real-time updates on events, politics, business and more.
August 19, 2022
GOTHENBURG, Sweden, Aug. 19, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2
August 17, 2022
The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF)Interim data have shown stabilization of the disease and an increase in lung capacity
August 17, 2022
("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...
August 9, 2022
/PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral...
June 14, 2022
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 study of LYT-100-COV (deupirfenidone) in ...
May 16, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
April 26, 2022
PureTech Announces Annual Results for Year Ended December 31, 2021 - read this article along with other careers information, tips and advice on BioSpace
March 4, 2022
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...
March 4, 2022
GOTHENBURG, Sweden, March 4, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2
February 24, 2022
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of...